skip to Main Content
Y2X Kate

Dr. Rochlin has spent her career immersed in early-stage biotech entrepreneurship as both a founder and a leader. She has served as Co-Founder and CSO of Immunovent, developer of a non-invasive oral swab allergy diagnostic. As Director of Scientific Affairs at Filament BioSolutions, she developed therapeutics for Oncology supportive care. As Director of Business Development for Biotagenics, she developed microbiome targeted therapeutics. With a B.A from the University of Pennsylvania in Molecular Biology and a Ph.D from Cornell University in Molecular Biology and Biochemistry, Dr. Rochlin is currently Chief Business Officer at a Paris-based nanotechnology company developing a platform that redefines therapeutic bioavailability and toxicity.

Back To Top